OCUGEN OCGN 深 沪
等待开盘 02-04 09:30:00 美东时间
1.442
+0.012
+0.84%
华盛通- 最 高1.495
- 今 开1.45
- 成交量 104.76万股
- 最 低 1.42
- 昨 收 1.43
- 总市值 4.50亿
- 52周最高 1.96
- 市盈率 静 --
- 换手率 0.34%
- 52周最低 0.515
- 委 比 14.22%
- 总股本 3.12亿
- 历史最高 18.77
- 量 比 0.87
- 振 幅 5.24%
- 历史最低 0.17
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ocugen strengthens balance sheet with new equity financing
The latest update is out from Ocugen ( ($OCGN) ). On January 22–23, 2026, Ocuge...
01-23 21:26
BUZZ-U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
BUZZ-U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks staged a modest recovery on Wednesday after the sharpest equities se
01-22 02:53
BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks staged a modest recovery on Wednesday after the sharpest e
01-21 23:49
BUZZ-Ocugen drops on stock offering
BUZZ-Ocugen drops on stock offering ** Ocugen OCGN.O shares down 7.2% premarket to $1.55 after biotech firm's follow-on prices ** Gene therapies developer for blindness diseases announces 15 mln shares at $1.50 for $22.5 mln gross proceeds ** Offering price represents 10.2% discount to stock's last
01-21 22:13
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
Ocugen, Inc. priced an underwritten offering of 15 million shares at $1.50 per share, raising $22.5 million. Proceeds will fund general corporate purposes, capital expenditures, and administrative expenses. RTW Investments leads the offering, with Oppenheimer & Co. as sole book-running manager. The offering is made under a SEC-registered shelf registration statement.
01-21 13:32
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Chardan Capital Maintains Buy on Ocugen, Maintains $7 Price Target
Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price target.
01-20 20:19
Ocugen Stock Is Surging Today: What's Driving The Action?
Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.
01-17 01:07
Ocugen posts mid-stage trial data for GA therapy
Ocugen (OCGN) traded higher in the premarket on Thursday after the company said that OCU410, its gene therapy for an eye disorder called geographic atrophy (GA) secondary to dry age-related macular de...
01-15 21:45
Ocugen Announces Publication Of Positive Phase 1 Gardian1 Trial Results For OCU410ST, Modifier Gene Therapy For Stargardt Disease, In Peer-Reviewed Journal Nature Eye
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patientsMALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or
01-12 19:32
